A revamped commercial strategy focused on three pillars: maximizing existing commercial customer business, advancing programs currently within the late-stage development pipeline toward commercialization, and winning impactful new business to fill the project pipeline.

Expected impact: Aims to deliver a 12% revenue compound annual growth rate (CAGR) and expand Adjusted EBITDA margins to more than 25% by the end of 2029.

Integration of a new high-speed, multi-purpose 5-head isolator filler designed for fill/finish operations across vials, cartridges, and pre-filled syringes, effectively doubling previous production capabilities.

Expected impact: Elevates Lifecore's maximum annual revenue potential to approximately $300 million and opens opportunities for less viscous products like proteins and antibodies.

Implementation of cost reduction initiatives, process improvements, and elevated quality standards across the organization to optimize operations.

Expected impact: Drives down SG&A and operating expenses to support margin expansion toward the mid-term goal of >25% Adjusted EBITDA margin.